Aug. 5 at 8:43 PM
$ADPT
🚨 🚨 🚨
MRD business achieved profitability with
$1.9M Adjusted EBITDA
Total revenue increased 36% YoY to
$58.9M
MRD revenue grew 42% YoY to
$49.9M
clonoSEQ test volume grew 37% to 25,321 tests
Operating expenses decreased 7% YoY
Net loss improved significantly from
$46.2M to
$25.6M YoY
Raised MRD revenue guidance to
$190-200M
Reduced cash burn guidance to
$45-55M
Company still reporting overall net loss of
$25.6M
Immune Medicine revenue showed modest 13% growth to
$8.9M
Interest income decreased from
$3.8M to
$2.4M YoY
Interest expense increased to
$2.9M from
$2.7M YoY
